NASDAQ:MEDS

TRxADE HEALTH Competitors

$4.50
+0.12 (+2.74 %)
(As of 06/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.17
$4.50
50-Day Range
$3.11
$6.67
52-Week Range
$3.10
$10.82
Volume166,925 shs
Average Volume1.84 million shs
Market Capitalization$36.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.14

TRxADE HEALTH (NASDAQ:MEDS) Vs. AYLA, SNPX, SCPH, FLGC, LGVN, and AYTU

Should you be buying MEDS stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to TRxADE HEALTH, including Ayala Pharmaceuticals (AYLA), Synaptogenix (SNPX), scPharmaceuticals (SCPH), Flora Growth (FLGC), Longeveron (LGVN), and Aytu Biopharma (AYTU).

Ayala Pharmaceuticals (NASDAQ:AYLA) and TRxADE HEALTH (NASDAQ:MEDS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, dividends, profitability, analyst recommendations, valuation, risk and institutional ownership.

Profitability

This table compares Ayala Pharmaceuticals and TRxADE HEALTH's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ayala Pharmaceuticals-899.65%-68.88%-60.56%
TRxADE HEALTH-18.74%-35.59%-31.28%

Valuation & Earnings

This table compares Ayala Pharmaceuticals and TRxADE HEALTH's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ayala Pharmaceuticals$3.71 million38.81$-30,150,000.00($3.06)-3.55
TRxADE HEALTH$17.12 million2.13$-2,540,000.00N/AN/A

TRxADE HEALTH has higher revenue and earnings than Ayala Pharmaceuticals.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Ayala Pharmaceuticals and TRxADE HEALTH, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ayala Pharmaceuticals00403.00
TRxADE HEALTH00303.00

Ayala Pharmaceuticals currently has a consensus price target of $24.00, indicating a potential upside of 120.69%. TRxADE HEALTH has a consensus price target of $12.50, indicating a potential upside of 177.78%. Given TRxADE HEALTH's higher possible upside, analysts clearly believe TRxADE HEALTH is more favorable than Ayala Pharmaceuticals.

Insider & Institutional Ownership

15.5% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 13.7% of TRxADE HEALTH shares are held by institutional investors. 2.9% of Ayala Pharmaceuticals shares are held by company insiders. Comparatively, 53.3% of TRxADE HEALTH shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

TRxADE HEALTH beats Ayala Pharmaceuticals on 7 of the 10 factors compared between the two stocks.

Synaptogenix (NASDAQ:SNPX) and TRxADE HEALTH (NASDAQ:MEDS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, valuation, dividends and profitability.

Analyst Ratings

This is a summary of recent recommendations for Synaptogenix and TRxADE HEALTH, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Synaptogenix0000N/A
TRxADE HEALTH00303.00

TRxADE HEALTH has a consensus price target of $12.50, indicating a potential upside of 177.78%. Given TRxADE HEALTH's higher probable upside, analysts plainly believe TRxADE HEALTH is more favorable than Synaptogenix.

Institutional and Insider Ownership

13.7% of TRxADE HEALTH shares are held by institutional investors. 53.3% of TRxADE HEALTH shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Synaptogenix and TRxADE HEALTH's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SynaptogenixN/AN/AN/AN/AN/A
TRxADE HEALTH$17.12 million2.13$-2,540,000.00N/AN/A

Synaptogenix has higher earnings, but lower revenue than TRxADE HEALTH.

Profitability

This table compares Synaptogenix and TRxADE HEALTH's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
SynaptogenixN/AN/AN/A
TRxADE HEALTH-18.74%-35.59%-31.28%

Summary

TRxADE HEALTH beats Synaptogenix on 5 of the 8 factors compared between the two stocks.

TRxADE HEALTH (NASDAQ:MEDS) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations and risk.

Valuation and Earnings

This table compares TRxADE HEALTH and scPharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TRxADE HEALTH$17.12 million2.13$-2,540,000.00N/AN/A
scPharmaceuticalsN/AN/A$-32,210,000.00($1.31)-3.99

TRxADE HEALTH has higher revenue and earnings than scPharmaceuticals.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for TRxADE HEALTH and scPharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TRxADE HEALTH00303.00
scPharmaceuticals01102.50

TRxADE HEALTH currently has a consensus price target of $12.50, suggesting a potential upside of 177.78%. scPharmaceuticals has a consensus price target of $11.00, suggesting a potential upside of 110.33%. Given TRxADE HEALTH's stronger consensus rating and higher possible upside, research analysts plainly believe TRxADE HEALTH is more favorable than scPharmaceuticals.

Risk and Volatility

TRxADE HEALTH has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.

Profitability

This table compares TRxADE HEALTH and scPharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TRxADE HEALTH-18.74%-35.59%-31.28%
scPharmaceuticalsN/A-34.02%-26.11%

Insider & Institutional Ownership

13.7% of TRxADE HEALTH shares are held by institutional investors. Comparatively, 62.9% of scPharmaceuticals shares are held by institutional investors. 53.3% of TRxADE HEALTH shares are held by company insiders. Comparatively, 4.1% of scPharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

TRxADE HEALTH beats scPharmaceuticals on 7 of the 11 factors compared between the two stocks.

Flora Growth (NASDAQ:FLGC) and TRxADE HEALTH (NASDAQ:MEDS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares Flora Growth and TRxADE HEALTH's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Flora GrowthN/AN/AN/AN/AN/A
TRxADE HEALTH$17.12 million2.13$-2,540,000.00N/AN/A

Flora Growth has higher earnings, but lower revenue than TRxADE HEALTH.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Flora Growth and TRxADE HEALTH, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Flora Growth0000N/A
TRxADE HEALTH00303.00

TRxADE HEALTH has a consensus target price of $12.50, suggesting a potential upside of 177.78%. Given TRxADE HEALTH's higher possible upside, analysts clearly believe TRxADE HEALTH is more favorable than Flora Growth.

Profitability

This table compares Flora Growth and TRxADE HEALTH's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Flora GrowthN/AN/AN/A
TRxADE HEALTH-18.74%-35.59%-31.28%

Institutional and Insider Ownership

13.7% of TRxADE HEALTH shares are owned by institutional investors. 53.3% of TRxADE HEALTH shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

TRxADE HEALTH beats Flora Growth on 5 of the 8 factors compared between the two stocks.

TRxADE HEALTH (NASDAQ:MEDS) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Institutional and Insider Ownership

13.7% of TRxADE HEALTH shares are held by institutional investors. Comparatively, 0.5% of Longeveron shares are held by institutional investors. 53.3% of TRxADE HEALTH shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares TRxADE HEALTH and Longeveron's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TRxADE HEALTH$17.12 million2.13$-2,540,000.00N/AN/A
Longeveron$5.63 million25.02$-3,720,000.00N/AN/A

TRxADE HEALTH has higher revenue and earnings than Longeveron.

Profitability

This table compares TRxADE HEALTH and Longeveron's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TRxADE HEALTH-18.74%-35.59%-31.28%
LongeveronN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for TRxADE HEALTH and Longeveron, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TRxADE HEALTH00303.00
Longeveron0000N/A

TRxADE HEALTH currently has a consensus price target of $12.50, indicating a potential upside of 177.78%. Given TRxADE HEALTH's higher probable upside, equities research analysts plainly believe TRxADE HEALTH is more favorable than Longeveron.

Summary

TRxADE HEALTH beats Longeveron on 6 of the 10 factors compared between the two stocks.

TRxADE HEALTH (NASDAQ:MEDS) and Aytu Biopharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

Profitability

This table compares TRxADE HEALTH and Aytu Biopharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TRxADE HEALTH-18.74%-35.59%-31.28%
Aytu Biopharma-74.44%-15.03%-9.07%

Volatility and Risk

TRxADE HEALTH has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Aytu Biopharma has a beta of -0.31, suggesting that its share price is 131% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for TRxADE HEALTH and Aytu Biopharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TRxADE HEALTH00303.00
Aytu Biopharma00303.00

TRxADE HEALTH currently has a consensus target price of $12.50, indicating a potential upside of 177.78%. Aytu Biopharma has a consensus target price of $9.50, indicating a potential upside of 69.95%. Given TRxADE HEALTH's higher probable upside, equities research analysts plainly believe TRxADE HEALTH is more favorable than Aytu Biopharma.

Institutional & Insider Ownership

13.7% of TRxADE HEALTH shares are owned by institutional investors. Comparatively, 35.5% of Aytu Biopharma shares are owned by institutional investors. 53.3% of TRxADE HEALTH shares are owned by company insiders. Comparatively, 6.6% of Aytu Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares TRxADE HEALTH and Aytu Biopharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TRxADE HEALTH$17.12 million2.13$-2,540,000.00N/AN/A
Aytu Biopharma$27.63 million5.09$-13,620,000.00N/AN/A

TRxADE HEALTH has higher earnings, but lower revenue than Aytu Biopharma.


TRxADE HEALTH Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.2$10.88+2.5%$144.00 million$3.71 million-3.88News Coverage
SNPX
Synaptogenix
0.3$10.22+7.9%$143.42 millionN/A0.00High Trading Volume
Gap Down
scPharmaceuticals logo
SCPH
scPharmaceuticals
1.3$5.23+0.4%$143.07 millionN/A-4.25
FLGC
Flora Growth
0.0$3.36+2.7%$141.20 millionN/A0.00Quiet Period Expiration
LGVN
Longeveron
0.0$7.42+1.1%$140.86 million$5.63 million0.00
Aytu Biopharma logo
AYTU
Aytu Biopharma
1.6$5.59+0.7%$140.71 million$27.63 million0.00High Trading Volume
RACA
Therapeutics Acquisition
0.0$9.98+0.3%$140.16 millionN/A0.00
Eton Pharmaceuticals logo
ETON
Eton Pharmaceuticals
1.5$5.71+4.4%$139.94 million$40,000.00-8.52
Nymox Pharmaceutical logo
NYMX
Nymox Pharmaceutical
0.8$1.69+6.5%$139.22 millionN/A-10.56
Eyenovia logo
EYEN
Eyenovia
1.6$5.33+0.8%$137.81 million$2 million-6.20Gap Up
Liquidia logo
LQDA
Liquidia
1.5$2.64+4.2%$137.21 million$740,000.00-1.78
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.4$3.76+0.3%$136.56 millionN/A-3.96
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
1.9$6.28+4.3%$135.81 millionN/A-1.40
Exicure logo
XCUR
Exicure
1.7$1.54+1.9%$135.51 million$16.61 million-3.50News Coverage
Beyond Air logo
XAIR
Beyond Air
1.9$6.17+17.3%$135.13 million$870,000.00-4.86Analyst Report
Insider Buying
High Trading Volume
News Coverage
Gap Up
IMARA logo
IMRA
IMARA
1.7$7.64+0.3%$134.77 millionN/A-2.56
DiaMedica Therapeutics logo
DMAC
DiaMedica Therapeutics
1.2$7.10+5.6%$133.38 million$500,000.00-9.10News Coverage
Catalyst Biosciences logo
CBIO
Catalyst Biosciences
1.7$4.23+1.2%$132.61 million$20.95 million-1.27
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$5.08+3.7%$132.39 million$4.25 million-1.12Gap Down
NuCana logo
NCNA
NuCana
1.4$2.73+1.1%$132.39 millionN/A-2.42
OncoSec Medical logo
ONCS
OncoSec Medical
1.6$3.36+0.6%$131.66 millionN/A-2.15
Concert Pharmaceuticals logo
CNCE
Concert Pharmaceuticals
1.7$4.08+2.5%$131.27 million$7.90 million-1.72
Capricor Therapeutics logo
CAPR
Capricor Therapeutics
1.2$5.72+5.4%$130.86 million$310,000.00-6.57High Trading Volume
AHAC
Alpha Healthcare Acquisition
1.7$10.16+0.3%$130.61 millionN/A0.00
Odonate Therapeutics logo
ODT
Odonate Therapeutics
1.6$3.38+0.9%$130.15 millionN/A-0.89
MediWound logo
MDWD
MediWound
1.2$4.77+0.8%$129.92 million$21.76 million-14.03
InflaRx logo
IFRX
InflaRx
1.2$3.00+4.7%$129.68 millionN/A-2.29
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$4.03+3.5%$129.61 million$3.45 million-3.36
Concord Medical Services logo
CCM
Concord Medical Services
0.6$2.95+0.0%$128.08 million$28.49 million0.00Gap Up
Cocrystal Pharma logo
COCP
Cocrystal Pharma
1.4$1.31+1.5%$127.68 million$2.01 million-7.71
ImmunoPrecise Antibodies logo
IPA
ImmunoPrecise Antibodies
0.0$6.64+3.2%$127.28 millionN/A0.00
ASLAN Pharmaceuticals logo
ASLN
ASLAN Pharmaceuticals
1.5$3.35+0.0%$127.27 million$3 million-8.37Gap Up
Kazia Therapeutics logo
KZIA
Kazia Therapeutics
1.1$9.75+1.3%$126.38 million$710,000.00-7.50Analyst Upgrade
Sio Gene Therapies logo
SIOX
Sio Gene Therapies
1.6$2.66+1.5%$125.69 millionN/A-3.17
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$3.93+1.0%$124.74 million$20,000.000.00Upcoming Earnings
CareCloud logo
MTBC
CareCloud
1.5$8.66+0.5%$124.71 million$105.12 million-5.93
Larimar Therapeutics logo
LRMR
Larimar Therapeutics
1.5$8.10+3.5%$124.48 millionN/A-2.31Analyst Downgrade
Otonomy logo
OTIC
Otonomy
1.5$2.18+2.3%$123.43 million$270,000.00-2.14News Coverage
BioLineRx logo
BLRX
BioLineRx
1.4$2.67+0.4%$122.99 millionN/A-1.64
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.4$2.25+2.2%$122.48 million$1.36 million-2.25
Liminal BioSciences logo
LMNL
Liminal BioSciences
1.0$4.09+1.2%$122.47 million$2.48 million-1.26
Biophytis logo
BPTS
Biophytis
0.0$10.64+4.1%$121.08 millionN/A0.00Gap Up
Champions Oncology logo
CSBR
Champions Oncology
1.8$9.01+4.3%$120.64 million$32.12 million-81.91
GlycoMimetics logo
GLYC
GlycoMimetics
1.7$2.34+1.7%$120.60 million$10.16 million-1.93
Galecto logo
GLTO
Galecto
1.6$4.74+2.7%$119.74 millionN/A-0.62
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
2.1$4.35+3.0%$119.50 million$33.42 million-6.13News Coverage
Evofem Biosciences logo
EVFM
Evofem Biosciences
1.8$1.16+0.9%$119.29 million$450,000.00-0.50Gap Down
Lipocine logo
LPCN
Lipocine
1.4$1.35+0.7%$119.19 million$170,000.00-4.50
Agile Therapeutics logo
AGRX
Agile Therapeutics
1.9$1.34+0.7%$118.27 million$750,000.00-1.91
CHFW
Consonance-HFW Acquisition
0.0$9.90+0.0%$118.17 millionN/A0.00
This page was last updated on 6/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.